Lilly inks agreement with South Korean RNAi developer for MASH asset
by
Contributor since / Followers
Contributor since / Followers
2 months ago
jetcityimage/iStock Editorial via Getty Images
- South Korea’s OliX Pharmaceuticals has negotiated a global licensing deal with Eli Lilly (NYSE:LLY) for the former’s RNAi candidate for metabolic-associated steatohepatitis (MASH), OLX75016.
- Terms call for Lilly to provide funding to complete the Phase 1 trial. Although financial terms were